Clinical trial Recruiting at 48 sites Interventional Ages 65 to 91 Women only

Preventing secondary hip fractures in postmenopausal women

Official title: Randomized Controlled Study of a Local Osteo-Enhancement Procedure (LOEP) to Prevent Secondary Hip Fractures in Osteoporotic Women Undergoing Treatment of Index Hip Fractures

Run by AgNovos Healthcare, LLC · NCT04796350 · Data updated 2026-11-12

This study is testing if a new treatment can help prevent additional hip fractures in postmenopausal women who have already broken a hip and are having surgery to fix it.

Quick facts

Study typeInterventional
Ages65 Years to 91 Years
SexWomen only
Enrollment2400 (estimated)
SponsorAgNovos Healthcare, LLC
Industry-sponsored
Locations66 sites (Innsbruck and 65 other locations)
StatusRecruiting
StartedApril 24, 2021
Main results expectedApril 1, 2027
Study endsApril 1, 2029
Registry record updatedMay 13, 2026
Trial IDNCT04796350 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are postmenopausal women aged 65 and older with a low-energy index hip fracture and additional risk factors for secondary fractures.

Probably not a fit

Patients who do not have a history of fragility fractures or those who are not postmenopausal may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of AGN1 LOEP treatment in preventing secondary hip fractures in postmenopausal women who have experienced an index hip fracture and are undergoing surgical repair. Up to 2400 subjects will be randomly assigned to either receive the AGN1 LOEP treatment on the unfractured hip or serve as a control group without the treatment. Participants will be monitored for a minimum of 5 years through scheduled visits to assess the incidence of secondary fractures. The study aims to provide insights into the long-term benefits of AGN1 LOEP in this high-risk population.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce the risk of secondary hip fractures in vulnerable postmenopausal women.

How similar studies have gone: Other studies have shown promise in similar approaches to fracture prevention, but the specific use of AGN1 LOEP is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Subject is a postmenopausal female at least 1-year post menses and at least 65 years of age and less than 92 years of age.
2. Subject presents with a low-energy index fragility hip fracture in one hip and will undergo surgical repair of the fractured hip.
3. Subject has at least one of the following additional risk factors for a secondary hip fracture (as determined by subject or legally authorized representative (LAR) interview or medical record review):

   * Documented falls assessment indicating subject is at moderate or high risk of falls
   * Falls history (2 or more falls in the previous 12 months)
   * History of vertigo, dizziness, or postural hypotension
   * Documented T-score \< -2.5 at the hip
   * Taking more than 3 daily prescription medications
   * Visual impairment as confirmed by one of the following:

     * Subject reports difficulty seeing
     * Lack of depth perception or vision loss in one eye
     * Macular degeneration
     * Cataracts
   * Prior non-hip fragility fracture
   * Cognitive frailty as assessed by SPMSQ (mild cognitive impairment determined by SPMSQ ≤ to 4) or delirium
   * Parkinson's disease stage 3 or 4
   * 10-year hip fracture probability \>15% using the FRAX® Fracture Risk Assessment Tool of the clinical site country
4. Subject is expected to be ambulatory after the hip fracture repair procedure. "Ambulatory" is defined as a patient's ability to ambulate beyond simple transfers with or without assistive devices.
5. Informed consent is provided by the subject or the subject's LAR. Use of an LAR to obtain patient consent requires that the patient must understand and be able to participate in post operative restrictions and requirements.
6. The subject's willingness, ability, and commitment to participate in screening, treatment, and all follow-up evaluations for the full duration of the study has been documented.

Exclusion Criteria:

1. Criterion omitted
2. Criterion omitted
3. Subject is currently enrolled in another interventional clinical study affecting the target hip.
4. Subject has a history of hip surgery or previous hip fracture on the target unfractured hip contralateral to the index hip fracture.
5. Subject has new fractures in addition to the index hip fracture at admission that, in the opinion of the investigator, would further compromise patient mobility, rehabilitation, or recovery.
6. Subject has an infection at the LOEP intended treatment site or has non-intact skin or acute traumatic injuries with open wounds close to the area of intended LOEP treatment.
7. Subject has a progressive increase in undiagnosed pain in the target hip contralateral to the index fractured hip over the previous 3 months that in the opinion of the Investigator may suggest underlying bone or joint pathology on the unfractured side.
8. Subject has radiological evidence of gross bony or joint pathology of the hip, including signs predictive of atypical femoral fractures (e.g. cortical beaking), or has been diagnosed and/or treated for atypical femoral fractures.
9. Criterion omitted
10. Subject has a history of metabolic bone disease other than osteoporosis (e.g., Paget's disease, renal osteodystrophy, or osteomalacia).
11. Criterion omitted
12. Subject has active cancer
13. Criterion omitted
14. Criterion omitted
15. Criterion omitted
16. Criterion omitted
17. Criterion omitted
18. Subject has end stage renal insufficiency defined as an estimated glomerular filtration rate (eGFR) \< 15 mL/min.
19. Criterion omitted
20. Criterion omitted
21. Subject has moderate or severe cognitive impairment as assessed by an SPMSQ of 5 or higher.
22. Subject has known allergies to calcium-based bone void fillers.
23. In the judgement of the Investigator, the subject is not a good study candidate (e.g., poor mental health, or active drug or alcohol abuse issues), and or subject would not be a good candidate to undergo an ELECTIVE orthopedic surgical procedure such as a total hip arthroplasty in her current medical, physiological condition.
24. Subject fails pre-operative or intraoperative eligibility criteria as specified in section 7.4.2. of the clinical investigation plan.

Where it's running

  • Innsbruck Hospital
    Innsbruck, Austria
    Recruiting
  • Ziekenhuis Oost-Limburg
    Genk, Belgium
    Recruiting
  • Ghent University Hospital
    Ghent, Belgium
    Recruiting
  • UZ Leuven
    Leuven, Belgium
    Recruiting
  • Vitaz Sint-Niklaas
    Sint-Niklaas, Belgium
    Recruiting
  • QEII Health Sciences Centre
    Halifax, Nova Scotia, Canada
    Recruiting
Show 44 more locations
  • Sunnybrook Health Sciences Centre
    North York, Ontario, Canada
    Recruiting
  • Aarhus University Hospital
    Aarhus, Denmark
    Recruiting
  • CHU de Nice
    Nice, Provence-Alpes-Côte d'Azur Region, France
    Recruiting
  • CHU Amiens
    Amiens, France
    Recruiting
  • CHU Grenoble-Alpes
    Grenoble, France
    Recruiting
  • Charite University Hosptial
    Berlin, Germany
    Recruiting
  • Universitatsklinikum Schleswig-Holstein
    Kiel, Germany
    Recruiting
  • Klinikum der Universität München
    München, Germany
    Recruiting
  • Azienda Ospedaliero Universitaria Careggi
    Florence, Italy
    Recruiting
  • ASST Gaetano Pini CTO
    Milan, Italy
    Recruiting
  • Policlinico Tor Vergata
    Rome, Italy
    Recruiting
  • CTO Torino
    Torino, Italy
    Recruiting
  • Akita City Hospital
    Akita, Akita, Japan
    Recruiting
  • Southern Tohoku General Hospital
    Kōriyama, Fukushima, Japan
    Recruiting
  • Hyogo Prefectural Nishinomiya Hospital
    Nishinomiya, Hyōgo, Japan
    Recruiting
  • Kagawa Rosai Hospital
    Marugame, Kagawa-ken, Japan
    Recruiting
  • Kanto Rosai Hospital
    Kawasaki, Kanagawa, Japan
    Recruiting
  • Okayama Medical Center
    Okayama, Okayama-ken, Japan
    Recruiting
  • St. Mary's Hospital
    Fukuoka, Japan
    Recruiting
  • Iwata City Hospital
    Iwata, Japan
    Recruiting
  • Shin-Yurigaoka General Hospital
    Kawasaki-shi, Japan
    Recruiting
  • National Hospital Organization Kumamoto Medical Center
    Kumamoto, Japan
    Recruiting
  • Saga-Ken Medical Centre Koseikan
    Saga, Japan
    Recruiting
  • Japanese Red Cross Shizuoka Hospital
    Shizuoka, Japan
    Recruiting
  • Deventer Hospital
    Deventer, Netherlands
    Recruiting
  • Maastricht UMC
    Maastricht, Netherlands
    Recruiting
  • Vall d'Hebron University Hospital
    Barcelona, Barcelona, Spain
    Recruiting
  • Valladolid University Clinic Hospital
    Valladolid, Valladolid, Spain
    Recruiting
  • Clinic de Barcelona
    Barcelona, Spain
    Recruiting
  • Hospital Universitario de Basurto
    Bilbao, Spain
    Recruiting
  • Galdakao-Usansolo Hospital
    Galdakao, Spain
    Recruiting
  • Hospital Neuro-Traumatológico de Jaén
    Jaén, Spain
    Recruiting
  • Hospital Clínico San Carlos
    Madrid, Spain
    Recruiting
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
    Recruiting
  • Hospital Universitario Infanta Leonor
    Madrid, Spain
    Recruiting
  • Hospital St Joan de Deu
    Manresa, Spain
    Recruiting
  • Mutua de Terrassa University Hospital
    Terrassa, Spain
    Recruiting
  • Leicester Royal Infirmary
    Leicester, England, United Kingdom
    Recruiting
  • Royal Infirmary of Edinburgh
    Edinburgh, Scotland, United Kingdom
    Recruiting
  • Queen Elizabeth Glasgow
    Glasgow, United Kingdom
    Recruiting
  • Wythenshawe Hospital Manchester
    Manchester, United Kingdom
    Recruiting
  • Nottingham University Hospitals, Queen's Medical Center
    Nottingham, United Kingdom
    Recruiting
  • Health Sciences Centre - Eastern Health
    St. John's, Newfoundland and Labrador, Canada
    Withdrawn
  • CHU Lyon
    Lyon, France
    Withdrawn

+16 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.